Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stayble Therapeutics ABOSTO:STABL 28 EV-to-EBITDA is -1.11 as of Aug. 14, 2026. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 400 Biotechnology companies, Stayble Therapeutics AB ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stayble Therapeutics AB's enterprise value is kr11.85 Mil.
Stayble Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-10.70 Mil. Therefore, Stayble Therapeutics AB's EV-to-EBITDA for today is -1.11.
The historical rank and industry rank for Stayble Therapeutics AB's EV-to-EBITDA or its related term are showing as below:
OSTO:STABL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.11 Med: 0 Max: 0
Current: -1.11
OSTO:STABL's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.485
vs OSTO:STABL: -1.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Stayble Therapeutics AB (OSTO:STABL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stayble Therapeutics AB's PE Ratio (TTM) for today is calculated as:
Stayble Therapeutics AB's share price for today is kr0.205.
Stayble Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:STABL vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Stayble Therapeutics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stayble Therapeutics AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stayble Therapeutics AB's EV-to-EBITDA falls into.
Stayble Therapeutics AB's current Enterprise Value is kr11.85 Mil.
Stayble Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-10.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stayble Therapeutics AB (OSTO:STABL) has a EV-to-EBITDA of -1.11 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stayble Therapeutics AB. According to the industry distribution chart, Stayble Therapeutics AB ranks #999999 out of 400 companies in the Biotechnology industry.
Is Stayble Therapeutics AB's EV-to-EBITDA too high?
Stayble Therapeutics AB's current EV-to-EBITDA is -1.11. Based on the distribution chart, Stayble Therapeutics AB ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stayble Therapeutics AB ranks #999999 out of 400 companies for EV-to-EBITDA. This places Stayble Therapeutics AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.49, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stayble Therapeutics AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stayble Therapeutics AB's current EV-to-EBITDA is -1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current EV-to-EBITDA of -1.11. The current EV-to-EBITDA is -1.11. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current EV-to-EBITDA is -1.11 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score
Get the complete analysis for OSTO:STABL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:STABL has been successfully added to your 
